Media ❯Investigations ❯Congressional Investigation ❯FDA Collaboration

Approval Process Irregularities

Biogen Discontinues Controversial Alzheimer's Drug Aduhelm

Company to Redirect Resources Toward Other Drug Candidates After Internal Review